UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance

Communications biology, 2018-01, Vol.1 (1), p.100-100, Article 100

2018

Volltextzugriff (PDF)

A highly effective one-pot synthesis of quinolines from o-nitroarylcarbaldehydes

Organic & biomolecular chemistry, 2007-01, Vol.5 (1), p.61-64

2007

Volltextzugriff (PDF)

Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives

Oncology reviews, 2013-04, Vol.7 (1), p.e3-e3

2013

Volltextzugriff (PDF)

Imidazo[1,5- a]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2

Bioorganic & medicinal chemistry letters, 2011-04, Vol.21 (7), p.2092-2097

2011

Volltextzugriff (PDF)

Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution

Future medicinal chemistry, 2012-03, Vol.4 (3), p.315-328

2012

Volltextzugriff (PDF)

Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy

Bioorganic & medicinal chemistry letters, 2011-02, Vol.21 (4), p.1176-1180

2011

Volltextzugriff (PDF)

Abstract A06: Biophysical and biochemical characterization of KRAS G12C inhibition through the SMARTTM platform

Molecular cancer research, 2020-05, Vol.18 (5_Supplement), p.A06-A06

2020

Volltextzugriff (PDF)

Abstract B37: Development of inhibitors of the activated form of KRAS G12C

Molecular cancer research, 2020-05, Vol.18 (5_Supplement), p.B37-B37

2020

Volltextzugriff (PDF)

Total Synthesis of (+)-Peloruside A

Organic letters, 2005-03, Vol.7 (7), p.1303-1305

2005

Volltextzugriff (PDF)

Discovery of a Novel Benzodiazepine Series of Cbl‑b Inhibitors for the Enhancement of Antitumor Immunity

ACS medicinal chemistry letters, 2023-12, Vol.14 (12), p.1848-1856

2023

Volltextzugriff (PDF)

Palladium-Catalyzed Direct Heck Arylation of Dual π-Deficient/π-Excessive Heteroaromatics. Synthesis of C-5 Arylated Imidazo[1,5-a]pyrazines

Organic letters, 2008-07, Vol.10 (14), p.2923-2926

2008

Volltextzugriff (PDF)

ARV-330: Androgen receptor PROTAC degrader for prostate cancer

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.267-267

2016

Volltextzugriff (PDF)

Abstract LB-097: Targeted degradation of the androgen receptor in prostate cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.LB-097-LB-097

2015

Volltextzugriff (PDF)

Abstract PR08: ARV-330: An androgen receptor PROTAC degrader for prostate cancer

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.PR08-PR08

2015

Volltextzugriff (PDF)

Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors

Bioorganic & medicinal chemistry letters, 2013-02, Vol.23 (4), p.979-984

2013

Volltextzugriff (PDF)

Toward a Total Synthesis of Peloruside A: Enantioselective Preparation of the C8−C19 Region

Organic letters, 2003-12, Vol.5 (26), p.4959-4961

2003

Volltextzugriff (PDF)

Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: Current status and future perspectives

Oncology reviews, 2013-04, Vol.7 (1)

2013

Volltextzugriff (PDF)

Abstract 2463: Discovery of imidazo[1,5- a ]pyrazine derived potent, selective and orally bioavailable ACK1 inhibitors

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2463-2463

2013

Volltextzugriff (PDF)

Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases

Bioorganic & medicinal chemistry letters, 2013-08, Vol.23 (15), p.4381-4387

2013

Volltextzugriff (PDF)

Synthesis of Substituted Imidazo[1,5-a]pyrazines via Mono-, Di-, and Directed Remote Metalation Strategies

Organic letters, 2009-11, Vol.11 (22), p.5118-5121

2009

Volltextzugriff (PDF)

Discovery of Novel Insulin-Like Growth Factor‑1 Receptor Inhibitors with Unique Time-Dependent Binding Kinetics

ACS medicinal chemistry letters, 2013-07, Vol.4 (7), p.627-631

2013

Volltextzugriff (PDF)

Abstract 2915: Discovery and characterization of OSI-296, a dual inhibitor of cMET and RON kinases

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2915-2915

2012

Volltextzugriff (PDF)

Abstract 3900: Discovery of FQIT: An imidazo[5,1- f ][1,2,4]triazine derived dual IGF-1R/IR inhibitor

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.3900-3900

2012

Volltextzugriff (PDF)

Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR

ACS medicinal chemistry letters, 2010-12, Vol.1 (9), p.510-515

2010

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(34)

Publikationsform

Sprache

Englisch
(36)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(18)
Life Sciences & Biomedicine
(12)
Chemistry
(11)
Chemistry, Organic
(10)
Physical Sciences
(10)
Chemistry, Medicinal
(8)
Pharmacology & Pharmacy
(8)
Animals
(6)
Cancer
(5)
Humans
(4)
Imidazoles - Chemistry
(4)
Molecular Structure
(4)
Protein Kinase Inhibitors - Chemistry
(4)
Pyrazines - Chemistry
(4)
Stereoisomerism
(4)
Antineoplastic Agents - Chemistry
(3)
Inhibitors
(3)
Insulin-Like Growth Factor-1 Receptor
(3)
Mice
(3)
Neoplasms - Drug Therapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance

A highly effective one-pot synthesis of quinolines from o-nitroarylcarbaldehydes

Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives

Imidazo[1,5- a]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2

Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution

Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy

Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl‑b Inhibitors

Abstract A06: Biophysical and biochemical characterization of KRAS G12C inhibition through the SMARTTM platform

Abstract B37: Development of inhibitors of the activated form of KRAS G12C

Total Synthesis of (+)-Peloruside A

Discovery of a Novel Benzodiazepine Series of Cbl‑b Inhibitors for the Enhancement of Antitumor Immunity

Palladium-Catalyzed Direct Heck Arylation of Dual π-Deficient/π-Excessive Heteroaromatics. Synthesis of C-5 Arylated Imidazo[1,5-a]pyrazines

ARV-330: Androgen receptor PROTAC degrader for prostate cancer

Abstract LB-097: Targeted degradation of the androgen receptor in prostate cancer

Abstract PR08: ARV-330: An androgen receptor PROTAC degrader for prostate cancer

Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors

Toward a Total Synthesis of Peloruside A: Enantioselective Preparation of the C8−C19 Region

Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: Current status and future perspectives

Abstract 2463: Discovery of imidazo[1,5- a ]pyrazine derived potent, selective and orally bioavailable ACK1 inhibitors

Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases

Synthesis of Substituted Imidazo[1,5-a]pyrazines via Mono-, Di-, and Directed Remote Metalation Strategies

Discovery of Novel Insulin-Like Growth Factor‑1 Receptor Inhibitors with Unique Time-Dependent Binding Kinetics

Abstract 2915: Discovery and characterization of OSI-296, a dual inhibitor of cMET and RON kinases

Abstract 3900: Discovery of FQIT: An imidazo[5,1- f ][1,2,4]triazine derived dual IGF-1R/IR inhibitor

Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR

Suchergebnisse filtern